A rapid and sensitive ultra-performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) method was developed and validated for the determination of troglitazone in mouse plasma. Troglitazone and its internal standard (IS), rosiglitazone, were separated on an ACQUITY UPLC BEH C(18) column (1.7 microm particle size, 50 x 2.1 mm i.d.) by gradient elution with water and methanol at a flow rate of 0.5 mL/min. The cycle time of each analysis was 2.5 min. Rosiglitazone and troglitazone eluted at 1.13 and 1.57 min, respectively, and were chromatographically resolved from the ion suppression and enhancement zones due to the biological matrix effect. Quantitation of the analytes was performed in electrospray negative ionization mode (ESI -ve) using multiple reaction monitoring (MRM) experiments. The weighted (1/x) calibration curve was quadratic over the plasma concentration range 1-2500 ng/mL with a correlation coefficient (r(2)) of 0.9966. The limit of quantitation (LOQ) of troglitazone in mouse plasma was lower than 1 ng/mL. The inter- and intra-day variations of the assay were lower than 12.1%; the overall accuracy ranged from 86.4-110.2% and recovery from spiked plasma was more than 60%. The developed method was successfully applied to determine troglitazone in mouse plasma after intraperitoneal administration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/rcm.2924 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unveiling the shield: Troglitazone's impact on epilepsy-induced nerve injury through ferroptosis inhibition.
CNS Neurosci Ther
August 2024
Department of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, P.R. China.
Article Synopsis
- Epilepsy affects around 50 million people worldwide, with many patients facing drug-refractory conditions despite available anti-epileptic drugs, indicating a need for new treatment options.
- This study investigates troglitazone (TGZ) as a potential neuroprotective agent against seizures and neuronal damage, employing both in vitro and in vivo models to assess its effects.
- Results showed that TGZ significantly reduced seizure severity and neuronal damage by inhibiting ferroptosis, preventing mitochondrial changes, and demonstrating efficacy in both cell models of toxicity.
Novel drug targets and molecular mechanisms for sarcopenia based on systems biology.
Biomed Pharmacother
July 2024
Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London SE1 9RT, UK; Science for Life Laboratory, KTH-Royal Institute of Technology, Stockholm SE-17165, Sweden. Electronic address:
Sarcopenia is a major public health concern among older adults, leading to disabilities, falls, fractures, and mortality. This study aimed to elucidate the pathophysiological mechanisms of sarcopenia and identify potential therapeutic targets using systems biology approaches. RNA-seq data from muscle biopsies of 24 sarcopenic and 29 healthy individuals from a previous cohort were analysed.
View Article and Find Full Text PDFDrug-induced impairment of mitochondrial fatty acid oxidation and steatosis: assessment of causal relationship with 45 pharmaceuticals.
Toxicol Sci
August 2024
MITOLOGICS S.A.S., Faculté de Médecine, Créteil 94000, France.
Drug-induced liver injury (DILI) represents a major issue for pharmaceutical companies, being a potential cause of black-box warnings on marketed pharmaceuticals, or drug withdrawal from the market. Lipid accumulation in the liver also referred to as steatosis, may be secondary to impaired mitochondrial fatty acid oxidation (mtFAO). However, an overall causal relationship between drug-induced mtFAO inhibition and the occurrence of steatosis in patients has not yet been established with a high number of pharmaceuticals.
View Article and Find Full Text PDFBioinformatics and system biology analysis revealed the crosstalk between COVID-19 and osteoarthritis.
Immun Inflamm Dis
December 2023
Department of Orthopedics, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Background: The global coronavirus disease 2019 (COVID-19) outbreak has significantly impacted public health. Moreover, there has been an association between the incidence and severity of osteoarthritis (OA) and the onset of COVID-19. However, the optimal diagnosis and treatment strategies for patients with both diseases remain uncertain.
View Article and Find Full Text PDFEffect of fenofibrate and selective PPARα modulator (SPPARMα), pemafibrate on KATP channel activity and insulin secretion.
BMC Res Notes
September 2023
Department of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
Article Synopsis
- Insulin secretion in pancreatic beta-cells is influenced by ATP-sensitive potassium (K) channels, and PPARα ligands like fenofibrate and pemafibrate are being studied for their effects on insulin release and glucose intolerance.
- In experiments with MIN6 cells, fenofibrate significantly increased insulin secretion in low glucose conditions, while pemafibrate did not enhance insulin secretion under any tested conditions.
- Fenofibrate reduced K channel activity, indicating its potential role in increasing insulin secretion, whereas pemafibrate had no effect on K channels or insulin mRNA expression.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!